ScFv‐Decorated PEG‐PLA‐Based Nanoparticles for Enhanced siRNA Delivery to Her2+ Breast Cancer

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ <i>neu</i> Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · see citing works

Cancer statistics, 2012

Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679 · see citing works

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,737 · see citing works

Nanoparticle therapeutics: an emerging treatment modality for cancer

Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · see citing works

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

Davis, M. E., Zuckerman, J. E., Choi, C. H. J., Seligson, D. B., Tolcher, A. W., Alabi, C. A., Yen, Y., Heidel, J. D., & Ribas, A. (2010) · Nature · doi:10.1038/nature08956 · Cited by 2,508 · see citing works

Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N. K., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J. J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,889 · see citing works

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotný, J., Margolies, M. N., Ridge, R. J., Bruccoleri, R. E., Haber, E., & Crea, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.5879 · Cited by 1,594 · see citing works

Single-Chain Antigen-Binding Proteins

Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S., Lee, T. T., Pope, S. H., Riordan, G. S., & Whitlow, M. D. (1988) · Science · doi:10.1126/science.3140379 · Cited by 1,509 · see citing works

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

Junutula, J. R., Raab, H. E., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,388 · see citing works

Quantum Dot−Aptamer Conjugates for Synchronous Cancer Imaging, Therapy, and Sensing of Drug Delivery Based on Bi-Fluorescence Resonance Energy Transfer

Bagalkot, V., Zhang, L., Levy‐Nissenbaum, E., Jon, S., Kantoff, P. W., Langer, R., & Farokhzad, O. C. (2007) · Nano Letters · doi:10.1021/nl071546n · Cited by 1,036 · see citing works

Ellman's reagent: 5,5′-dithiobis(2-nitrobenzoic acid)—a reexamination

Riddles, P. W., Blakeley, R. L., & Zerner, B. (1979) · Analytical Biochemistry · doi:10.1016/0003-2697(79)90792-9 · Cited by 1,022 · see citing works

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

Shen, B., Xu, K., Liu, L., Raab, H. E., Bhakta, S., Kenrick, M., Parsons-Reponte, K., Tien, J., Yu, S., Mai, E., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2108 · Cited by 1,011 · see citing works

Cell cycle kinases as therapeutic targets for cancer

Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 906 · see citing works

Treatment of HER2-positive breast cancer: current status and future perspectives

Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 860 · see citing works

Targeting polo-like kinase 1 for cancer therapy

Strebhardt, K., & Ullrich, A. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1841 · Cited by 843 · see citing works

Biology of HER2 and Its Importance in Breast Cancer

Yarden, Y. (2001) · Oncology · doi:10.1159/000055396 · Cited by 739 · see citing works

Drug delivery with upconversion nanoparticles for multi-functional targeted cancer cell imaging and therapy

Wang, C., Cheng, L., & Liu, Z. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.09.069 · Cited by 666 · see citing works

Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.

Wright, C., Angus, B., Nicholson, S., Sainsbury, J. R. C., Cairns, J., Gullick, W. J., Kelly, P., Harris, A. L., & Horne, C. H. W. (1989) · PubMed · Cited by 582 · see citing works

T Cell-Specific siRNA Delivery Suppresses HIV-1 Infection in Humanized Mice

Kumar, P., Ban, H., Kim, S. S., Wu, H., Pearson, T., Greiner, D. L., Laouar, A., Yao, J., Haridas, V., Habiro, K., et al. (2008) · Cell · doi:10.1016/j.cell.2008.06.034 · Cited by 573 · see citing works

Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer

Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541 · see citing works

Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target

Peer, D., Park, E. J., Morishita, Y., Carman, C. V., & Shimaoka, M. (2008) · Science · doi:10.1126/science.1149859 · Cited by 491 · see citing works

Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells

Liu, X., & Erikson, R. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031523100 · Cited by 474 · see citing works

Polo-like kinases: a team that plays throughout mitosisPreprint

Glover, D. M., Hagan, I., & Tavares, Á. A. (1998) · Genes & Development · doi:10.1101/gad.12.24.3777 · Cited by 427 · see citing works

Simultaneous Delivery of siRNA and Paclitaxel via a “Two-in-One” Micelleplex Promotes Synergistic Tumor Suppression

Sun, T., Du, J., Yao, Y., Mao, C., Dou, S., Huang, S., Zhang, P., Leong, K. W., Song, E., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn103349h · Cited by 406 · see citing works

Polo-like kinases (Plks) and cancer

Takai, N., Hamanaka, R., Yoshimatsu, J., & Miyakawa, I. (2005) · Oncogene · doi:10.1038/sj.onc.1208272 · Cited by 391 · see citing works

Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA

Heidel, J. D., Yu, Z., Liu, J. Y.-C., Rele, S. M., Liang, Y., Zeidan, R. K., Kornbrust, D. J., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701458104 · Cited by 382 · see citing works

Polo-like kinases and oncogenesis

Eckerdt, F., Yuan, J., & Strebhardt, K. (2005) · Oncogene · doi:10.1038/sj.onc.1208273 · Cited by 363 · see citing works

Layer-by-Layer Nanoparticles with a pH-Sheddable Layer for<i>in Vivo</i>Targeting of Tumor Hypoxia

Poon, Z., Chang, D., Zhao, X., & Hammond, P. T. (2011) · ACS Nano · doi:10.1021/nn200876f · Cited by 343 · see citing works

Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice

Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37515 · Cited by 337 · see citing works

Effect of RNA Silencing of Polo-Like Kinase-1 (PLK1) on Apoptosis and Spindle Formation in Human Cancer Cells

Spänkuch, B., Bereiter‐Hahn, J., Kaufmann, M., & Strebhardt, K. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.24.1863 · Cited by 330 · see citing works

αVβ3 Integrin-Targeted PLGA-PEG Nanoparticles for Enhanced Anti-tumor Efficacy of a Pt(IV) Prodrug

Graf, N., Bielenberg, D. R., Kolishetti, N., Muus, C., Banyard, J., Farokhzad, O. C., & Lippard, S. J. (2012) · ACS Nano · doi:10.1021/nn301148e · Cited by 327 · see citing works

Folate-Mediated Cell Targeting and Cytotoxicity Using Thermoresponsive Microgels

Nayak, S., Lee, H., Chmielewski, J. A., & Lyon, L. A. (2004) · Journal of the American Chemical Society · doi:10.1021/ja0474143 · Cited by 317 · see citing works

Aptamer-Based Tumor-Targeted Drug Delivery for Photodynamic Therapy

Shieh, Y.-A., Yang, S., Wei, M., & Shieh, M. (2010) · ACS Nano · doi:10.1021/nn901374b · Cited by 300 · see citing works

Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody

Lukyanov, A. N., ElBayoumi, T. A., Chakilam, A. R., & Torchilin, V. P. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.08.007 · Cited by 294 · see citing works

Sheddable Ternary Nanoparticles for Tumor Acidity-Targeted siRNA Delivery

Yang, X., Du, J., Dou, S., Mao, C., Long, H., & Wang, J. (2011) · ACS Nano · doi:10.1021/nn204240b · Cited by 284 · see citing works

Targeting Polo-like Kinase in Cancer Therapy

Degenhardt, Y., & Lampkin, T. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1380 · Cited by 264 · see citing works

Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy

Yang, X., Dou, S., Sun, T., Mao, C., Wang, H., & Wang, J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.035 · Cited by 242 · see citing works

Delivery of Small Interfering RNA by Peptide-Targeted Mesoporous Silica Nanoparticle-Supported Lipid Bilayers

Ashley, C. E., Carnes, E. C., Epler, K. E., Padilla, D. P., Phillips, G. K., Castillo, R., Wilkinson, D., Wilkinson, B., Burgard, C., Kalinich, R. M., et al. (2012) · ACS Nano · doi:10.1021/nn204102q · Cited by 241 · see citing works

Chlorotoxin Labeled Magnetic Nanovectors for Targeted Gene Delivery to Glioma

Kievit, F. M., Omid Veiseh, A., Fang, C., Bhattarai, N., Lee, D., Ellenbogen, R. G., & Zhang, M. (2010) · ACS Nano · doi:10.1021/nn1008512 · Cited by 225 · see citing works

Multifunctional SPIO/DOX-loaded wormlike polymer vesicles for cancer therapy and MR imaging

Yang, X., Grailer, J. J., Rowland, I. J., Javadi, A., Hurley, S. A., Steeber, D. A., & Gong, S. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.08.039 · Cited by 217 · see citing works

A review of the current status of siRNA nanomedicines in the treatment of cancer

Resnier, P., Montier, T., Mathieu, V., Benoît, J., & Passirani, C. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.060 · Cited by 209 · see citing works

F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery

Hu, Q., Gu, G., Liu, Z., Jiang, M., Kang, T., Miao, D., Tu, Y., Pang, Z., Song, Q., Yao, L., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.10.048 · Cited by 194 · see citing works

Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2 + Breast Cancer Growth and Metastasis

Yao, Y., Sun, T., Huang, S., Dou, S., Lin, L., Chen, J.-N., Ruan, J.-B., Mao, C., Yu, F., Zeng, M., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003601 · Cited by 189 · see citing works

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

Olmos, D., Barker, D. S., Sharma, R., Brunetto, A. T., Yap, T. A., Taegtmeyer, A. B., Barriuso, J., Medani, H., Degenhardt, Y., Allred, A. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2946 · Cited by 169 · see citing works

Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab’ fragments

Béduneau, A., Saulnier, P., Hindré, F., Clavreul, A., Leroux, J., & Benoît, J. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.05.014 · Cited by 161 · see citing works

Single-Step Assembly of Cationic Lipid–Polymer Hybrid Nanoparticles for Systemic Delivery of siRNA

Yang, X., Dou, S., Wang, Y., Long, H., Xiong, M., Mao, C., Yao, Y., & Wang, J. (2012) · ACS Nano · doi:10.1021/nn300500u · Cited by 159 · see citing works

Targeted Delivery of Cisplatin to Lung Cancer Using ScFvEGFR-Heparin-Cisplatin Nanoparticles

Peng, X.-H., Wang, Y., Huang, D., Wang, Y., Shin, H. J., Chen, Z., Spewak, M. B., Mao, H. Z., Wang, X., Wang, Y., et al. (2011) · ACS Nano · doi:10.1021/nn202410f · Cited by 158 · see citing works

The Predictive Value of HER2 in Breast Cancer

Piccart, M. J., Lohrisch, C. A., Leo, A. D., & Larsimont, D. (2001) · Oncology · doi:10.1159/000055405 · Cited by 155 · see citing works

Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: Synthesis, preparation and in vivo evaluation

Zhang, P., Hu, L., Yin, Q., Zhang, Z., Feng, L., & Li, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.031 · Cited by 144 · see citing works

Evolving novel anti-HER2 strategies

Jones, K. L., & Buzdar, A. U. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70315-8 · Cited by 112 · see citing works

A Novel Solid Lipid Nanoparticle Formulation for Active Targeting to Tumor αvβ3 Integrin Receptors Reveals Cyclic RGD as A Double‐Edged Sword

Shuhendler, A. J., Prasad, P., Leung, M. Y. K., Rauth, A. M., DaCosta, R. S., & Wu, X. Y. (2012) · Advanced Healthcare Materials · doi:10.1002/adhm.201200006 · Cited by 111 · see citing works

EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma

Gao, J., Yu, Y., Zhang, Y., Song, J., Chen, H., Li, W., Qian, W., Deng, L., Kou, G., Chen, J., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.09.035 · Cited by 109 · see citing works

Antibody‐Functionalized Magnetic Polymersomes: In vivo Targeting and Imaging of Bone Metastases using High Resolution MRI

Pourtau, L., Oliveira, H., Thévenot, J., Wan, Y., Brisson, A. R., Sandre, O., Miraux, S., Thiaudière, E., & Lecommandoux, S. (2013) · Advanced Healthcare Materials · doi:10.1002/adhm.201300061 · Cited by 100 · see citing works

Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide

Chen, X., Wang, X., Wang, Y., Yang, L., Hu, J., Xiao, W., Fu, A., Cai, L., Li, X., & Ye, X. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.007 · Cited by 99 · see citing works

PLK1 as an oncology target: current status and future potential

McInnes, C., & Wyatt, M. D. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.002 · Cited by 91 · see citing works

N-acetylgalactosamine functionalized mixed micellar nanoparticles for targeted delivery of siRNA to liver

Wang, H., Xiong, M., Wang, Y., Zhu, J., & Wang, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.12.017 · Cited by 90 · see citing works

An Open-Label, Phase I Study of the Polo-like Kinase-1 Inhibitor, BI 2536, in Patients with Advanced Solid Tumors

Hofheinz, R., Al‐Batran, S., Hochhaus, A., Jäger, E., Reichardt, V. L., Fritsch, H., Trommeshauser, D., & Munzert, G. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0318 · Cited by 86 · see citing works

Nanoparticles functionalised with recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells

Vigor, K., Kyrtatos, P. G., Minogue, S., Al‐Jamal, K. T., Kogelberg, H., Tolner, B., Kostarelos, K., Beǵent, R. H. J., Pankhurst, Q. A., Lythgoe, M. F., et al. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.10.036 · Cited by 83 · see citing works

Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells

Li, X., Stuckert, P., Bosch, I., Marks, J. D., & Marasco, W. A. (2001) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700337 · Cited by 77 · see citing works

Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles

Qian, C., Wang, Y., Chen, Y., Zeng, L., Zhang, Q., Shuai, X., & Huang, K. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.04.056 · Cited by 67 · see citing works

Silencing of Polo-Like Kinase (Plk) 1 via siRNA Causes Inhibition of Growth and Induction of Apoptosis in Human Esophageal Cancer Cells

Bu, Y., Yang, Z., Li, Q., & Song, F. (2008) · Oncology · doi:10.1159/000151367 · Cited by 62 · see citing works

Downregulation of Plk1 Expression By Receptor-Mediated Uptake of Antisense Oligonucleotide-Loaded Nanoparticles

Spänkuch, B., Steinhauser, I., Wartlick, H., Kurunci‐Csacsko, E., Strebhardt, K., & Langer, K. (2008) · Neoplasia · doi:10.1593/neo.07916 · Cited by 52 · see citing works

PLK1 as a potential drug target in cancer therapy

Goh, K. C., Wang, H., Yu, N., Zhou, Y., Yin, Z., Lim, Z.-Y., Sangthongpitag, K., Fang, L., Du, M., Wang, X., et al. (2004) · Drug Development Research · doi:10.1002/ddr.10392 · Cited by 25 · see citing works

A Phase I and pharmacokinetic study of HMN-214, a novel oral polo-like kinase inhibitor, in patients with advanced solid tumors

Hoff, D. D. V., Taylor, C., Rubin, S. D., Cohen, J. D., & Garland, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3034 · Cited by 20 · see citing works

A comprehensive comparison between camelid nanobodies and single chain variable fragments

Asaadi, Y., Jouneghani, F. F., Janani, S., & Rahbarizadeh, F. (2021) · Biomarker Research · doi:10.1186/s40364-021-00332-6 · Cited by 209 · see citing works

Poly(Ethylene Glycol)–Polylactide Micelles for Cancer Therapy

Wang, J., Li, S., Han, Y., Guan, J., Chung, S., Wang, C., & Li, D. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00202 · Cited by 155 · see citing works

Transforming Intratumor Bacteria into Immunopotentiators to Reverse Cold Tumors for Enhanced Immuno-chemodynamic Therapy of Triple-Negative Breast Cancer

Liu, X., Sun, M., Pu, F., Ren, J., & Qu, X. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c09472 · Cited by 143 · see citing works

Design of thiol- and light-sensitive degradable hydrogels using Michael-type addition reactions

Kharkar, P. M., Kiick, K. L., & Kloxin, A. M. (2015) · Polymer Chemistry · doi:10.1039/c5py00750j · Cited by 137 · see citing works

Responsive Nanocarriers as an Emerging Platform for Cascaded Delivery of Nucleic Acids to Cancer

Liu, Y., Xu, C., Iqbal, S., Yang, X., & Wang, J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.03.004 · Cited by 130 · see citing works

Promoting tumor penetration of nanoparticles for cancer stem cell therapy by TGF-β signaling pathway inhibition

Zuo, Z.-Q., Chen, K., Yu, X., Zhao, G., Shen, S., Cao, Z., Luo, Y., Wang, Y., & Wang, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.12.014 · Cited by 126 · see citing works

Tumor acidity-sensitive linkage-bridged block copolymer for therapeutic siRNA delivery

Xu, C., Zhang, H., Sun, C., Liu, Y., Shen, S., Yang, X., Zhu, Y., & Wang, J. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.02.031 · Cited by 106 · see citing works

The use of nanoparticles as a promising therapeutic approach in cancer immunotherapy

Hosseini, M., Haji-Fatahaliha, M., Jadidi-Niaragh, F., Majidi, J., & Yousefi, M. (2015) · Artificial Cells Nanomedicine and Biotechnology · doi:10.3109/21691401.2014.998830 · Cited by 80 · see citing works

Preferential tumor accumulation and desirable interstitial penetration of poly(lactic-co-glycolic acid) nanoparticles with dual coating of chitosan oligosaccharide and polyethylene glycol-poly(d,l-lactic acid)

Wang, G., Chen, Y., Wang, P., Wang, Y., Hong, H., Li, Y., Qian, J., Yuan, Y., Yu, B., & Liu, C. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.10.017 · Cited by 76 · see citing works

Therapeutic Targeting in Nanomedicine: the Future Lies in Recombinant Antibodies

Pietersz, G. A., Wang, X., Yap, M. L., Lim, B., & Peter, K. (2017) · Nanomedicine · doi:10.2217/nnm-2017-0043 · Cited by 71 · see citing works

Selective transferrin coating as a facile strategy to fabricate BBB-permeable and targeted vesicles for potent RNAi therapy of brain metastatic breast cancer in vivo

Wei, Y., Sun, Y., Wei, J., Qiu, X., Meng, F., Storm, G., & Zhong, Z. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.048 · Cited by 63 · see citing works

Tumor acidity-activatable TAT targeted nanomedicine for enlarged fluorescence/magnetic resonance imaging-guided photodynamic therapy

Gao, M., Fan, F., Li, D., Yu, Y., Mao, K., Sun, T., Qian, H., Tao, W., & Yang, X. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.04.013 · Cited by 60 · see citing works

Development of “CLAN” Nanomedicine for Nucleic Acid Therapeutics

Xu, C., Iqbal, S., Shen, S., Luo, Y., Yang, X., & Wang, J. (2019) · Small · doi:10.1002/smll.201900055 · Cited by 55 · see citing works

Nanoparticle-mediated delivery of suicide genes in cancer therapy

Vago, R., Collico, V., Zuppone, S., Prosperi, D., & Colombo, M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.007 · Cited by 48 · see citing works

Therapeutic siRNA for drug-resistant HER2-positive breast cancer

Gu, S., Hu, Z., Ngamcherdtrakul, W., Castro, D. J., Morry, J., Reda, M. M., Gray, J. W., & Yantasee, W. (2016) · Oncotarget · doi:10.18632/oncotarget.7409 · Cited by 45 · see citing works

Use of Single-Chain Antibody Derivatives for Targeted Drug Delivery

Safdari, Y., Ahmadzadeh, V., Khalili, M., Jaliani, H. Z., Zarei, V., & Moghadam, V. E. (2016) · Molecular Medicine · doi:10.2119/molmed.2016.00043 · Cited by 44 · see citing works

Targeting HER2-breast tumors with scFv-decorated bimodal nanoprobes

Alric, C., Hervé-Aubert, K., Aubrey, N., Melouk, S., Lajoie, L., Même, W., Même, S., Courbebaisse, Y., Ignatova, A. A., Feofanov, A. V., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0341-6 · Cited by 44 · see citing works

Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment

Liang, X., Wang, Y., Shi, H., Dong, M., Han, H., & Li, Q. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s304526 · Cited by 41 · see citing works

Poly(lactic acid) Controlled Drug Delivery

Li, J., Ding, J., Liu, T., Liu, J. F., Yan, L., & Chen, X. (2017) · Advances in polymer science · doi:10.1007/12_2017_11 · Cited by 34 · see citing works

Targeted Delivery of siRNA Therapeutics to Malignant Tumors

Leng, Q., Woodle, M. C., & Mixson, A. J. (2017) · Journal of Drug Delivery · doi:10.1155/2017/6971297 · Cited by 30 · see citing works

Tumor-Homing Peptides as Crucial Component of Magnetic-Based Delivery Systems: Recent Developments and Pharmacoeconomical Perspective

Milewska, S., Sadowska, A. J., Stefaniuk, N., Misztalewska‐Turkowicz, I., Wilczewska, A. Z., Car, H., & Niemirowicz-Laskowska, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116219 · Cited by 29 · see citing works

Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment

Ngamcherdtrakul, W., Castro, D. J., Gu, S., Morry, J., Reda, M. M., Gray, J. W., & Yantasee, W. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.005 · Cited by 28 · see citing works

Biologicals to direct nanotherapeutics towards HER2-positive breast cancers

Kumar, G., Nandakumar, K., Mutalik, S., & Rao, C. M. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102197 · Cited by 24 · see citing works

Delivery of paclitaxel using nanoparticles composed of poly(ethylene oxide)-b-poly(butylene oxide) (PEO-PBO)

Wang, L., Ju, Y., Zhang, X., Zhang, Y., Xu, C., Lee, R. J., Yu, G., Yu, B., & Teng, L. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.11.013 · Cited by 23 · see citing works

A comprehensive review of the biomaterial-based multifunctional nanocarriers for therapeutic applications in breast cancer

Shettiwar, A., Gupta, U., Paul, P., Nair, R., Aalhate, M., Mahajan, S., Maji, I., Guru, S., Mehra, N., & Singh, P. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104990 · Cited by 16 · see citing works

A promising cancer diagnosis and treatment strategy: Targeted cancer therapy and imaging based on antibody fragment

Zhao, X., Ning, Q., Mo, Z., & Tang, S. (2019) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.1080/21691401.2019.1657875 · Cited by 16 · see citing works

Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application

Khantasup, K., Chantima, W., Sangma, C., Poomputsa, K., & Dharakul, T. (2015) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2015.0036 · Cited by 14 · see citing works

Aptamer‐siRNA chimeras: Promising tools for targeting HER2 signaling in cancer

Dhanya, C. R., Mary, A. S., & Madhavan, M. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14143 · Cited by 13 · see citing works

Noncationic polymer-assisted carrier for nucleic acid drug delivery

Su, M., Chen, J., Zhu, Y., Chen, C., Zhang, Y., & Yang, X. (2024) · Science China Materials · doi:10.1007/s40843-024-3048-0 · Cited by 13 · see citing works

Targeted approaches for HER2 breast cancer therapy: News from nanomedicine?

Mazzucchelli, S. (2014) · World Journal of Pharmacology · doi:10.5497/wjp.v3.i4.72 · Cited by 13 · see citing works

Click modified amphiphilic graft copolymeric micelles of poly(styrene-alt-maleic anhydride) for combinatorial delivery of doxorubicin and plk-1 siRNA in cancer therapy

Alex, M. R. A., Veeranarayanan, S., Poulose, A. C., Nehate, C., Kumar, D. S., & Koul, V. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb02094a · Cited by 12 · see citing works

Biomimetic Modification of siRNA/Chemo Drug Nanoassemblies for Targeted Combination Therapy in Breast Cancer

Xu, J., Li, R., Yan, D., & Zhu, L. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c11064 · Cited by 10 · see citing works

Indocyanine green-laden poly(ethylene glycol)-block-polylactide (PEG-b-PLA) nanocapsules incorporating reverse micelles: Effects of PEG-b-PLA composition on the nanocapsule diameter and encapsulation efficiency

Watanabe, T., Sakamoto, Y., Inooka, T., Kimura, Y., & Ono, T. (2017) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2017.02.039 · Cited by 10 · see citing works

Single-helical formyl β-glucan effectively deliver CpG DNA with poly(dA) to macrophages for enhanced vaccine effects

Xu, Y., Liang, M., Huang, J., Fan, Y., Long, H., Chen, Q., Ren, Z., Wu, C., & Wang, Y. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.10.258 · Cited by 6 · see citing works

D2B antibody and its scFvD2B fragment in nanomedicine: promising tools in the theranostics of prostate cancer

Mitri, N., Rahme, K., Fracasso, G., & Ghanem, E. (2021) · Advances in Natural Sciences Nanoscience and Nanotechnology · doi:10.1088/2043-6262/ac2747 · Cited by 4 · see citing works

Breast cancer immunotherapy using scFv antibody-based approaches, a systematic review

Heidarnejad, K., Faraji, S. N., Mahfoozi, S., Ghasemi, Z., Dashti, F. S., Asadi, M., & Ramezani, A. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.111090 · Cited by 2 · see citing works

Desarrollo, producción y caracterización parcial de un fragmento variable de Ig de cadena sencilla fusionado al Fc de la IgG1 humana (scFv-Fc) con especificidad anti-HER2

Laboratorio de Patología Celular y Molecular, C. D. M. E., Hoyos, R. G., Sandoval, A. A. P., Instituto de Hematología y Oncología, U. C. D. V., Porras, V., Instituto de Hematología y Oncología, U. C. D. V., Montaño, R. F., Laboratorio de Patología Celular y Molecular, C. D. M. E., Fuenmayor, J., & Laboratorio de Patología Celular y Molecular, C. D. M. E. (2018) · Investigación Clínica · doi:10.22209/ic.v59n3a01 · Cited by 1 · see citing works

RNA delivery for cancer gene therapy

Öncül, S., Amero, P., Rodriguez‐Aguayo, C., Sood, A. K., Călin, G. A., & Lopez‐Berestein, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821595-1.00004-x

DEVELOPMENT OF AMPHOTERICIN-B LOADED NANOPARTICLES AND EVALUATION THE ANTIMICROBIAL POTENCY

Öz, U. C., Rızvanoğlu, S. S., Abamor, E. Ş., CENGİZ, G., Berber, H., Derman, S., Eryılmaz, M., & Bozkır, A. (2023) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.33483/jfpau.1352203

Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2 + Breast Cancer Growth and Metastasis

Yao, Y., Sun, T., Huang, S., Dou, S., Lin, L., Chen, J.-N., Ruan, J.-B., Mao, C., Yu, F., Zeng, M., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003601 · Cited by 189 · see citing works

Abstract 5416: Development of a nanoparticle platform for the targeted delivery of siRNA to HER2-positive breast cancers

Goodyear, S. M. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-5416

Abstract C134: Herceptin-targeted siRNA nanoparticles inhibit the growth Her2-positive breast cancer tumors in vivo.

Zuckerman, J. E., Han, H., Medrano, L. J., Choi, C. H. J., & Davis, M. E. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-c134

et al.Yan-dan Yao Cancer Growth and Metastasis Breast+Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2 Editor's Summary

(2016)

Development of hyaluronic acid–anchored polycaprolactone nanoparticles for efficient delivery of PLK1 siRNA to breast cancer

Jain, D., & Yadav, A. K. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01288-2 · Cited by 7 · see citing works